Morales-Rivero A, Torres SG, Santos R, Basante ARA, Ortiz MJF, Crail MED

Language: Spanish
References: 7
Page: 26-30
PDF size: 170.83 Kb.

ABSTRACT

Introduction: Within the spectrum of psychiatric illnesses one of the most complex is the schizoaffective disorder due to the fact that both, its diagnosis and pharmacological management are challenging. This disease combines cardinal symptoms of schizophrenia and mood disorders symptoms. The aim of the treatment focuses on improving both psychotic symptoms and mood stabilization. Benzodiazepines are frequently used, and should be gradually reduced in order to prevent either a relapse or withdrawal symptoms. Here, we report the case of a 31-yearold female patient that after a gradual reduction of benzodiazepines and the suspension of clonazepam developed depressive symptoms, which subsided after the drug reinstatement.
Case report: A 31-year-old female with no relevant past medical history developed psychotic symptoms that required hospitalization. Maniac symptoms appeared and therefore, the diagnosis was a manic episode with psychotic symptoms. Antipsychotic drugs, a mood stabilizer and benzodiazepines were the treatment used and the patient showed clinical improvement. She was free of clinical manifestations for two years, until the patient presented a psychotic episode without mood symptoms; therefore she was diagnosed with schizoaffective disorder according to the DSM V criteria. After clinical improvement drugs were decreased gradually. Following the suspension of clonazepam the patient had depressive symptoms that disappeared after the reinstatement of the drug.
Discussion: The sudden appearance of depressive symptoms was considered as a possible relapse linked to the underlying disease. Strictly speaking, the patient did not meet the criteria for benzodiazepine withdrawal syndrome. The literature reports that in some cases depressive symptoms may be part of this spectrum, however neither a temporality nor any other relevant characteristics were specified. After restarting the drug at the lowest dose that the patient used, total remission of the major depressive disorder was achieved in less than two weeks. This allowed us to establish, at our discretion, a direct link between the suspension of clonazepam and the appearance of these symptoms.
Conclusion: Although the management depends on the characteristics of each patient and the physician preferences, it is worth keeping in mind the possibility of unusual symptoms that may appear even by following the correct guidelines established for a correct decrease doses and the suspension of benzodiazepines.

REFERENCES

1. Lindenmayer JP, Kaur A. Antipsychotic Management of Schizoaffective Disorder: A Review. Drugs. 2016;76(5):589-604.

2. Rink L, Pagel T, Franklin J, Baethge C. Characteristics and heterogeneity of schizoaffective disorder compared with unipolar depression and schizophrenia - a systematic literature review and meta-analysis. Journal of affective disorders. 2016;191:8-14.

3. American Psychiatric Association. Desk reference to the diagnostic criteria from DSM-5. Washington, DC: American Psychiatric Publishing; 2013. xlviii, 395 p. p.

4. Stahl SM. Stahl’s Essential Psychopharmacology: Cambridge; 2013. 608 p.

5. Ray R, Roychowdhury J. Stability of psychiatric diagnosis. Indian journal of psychiatry. 1984;26(2):164-8.

6. Rabinowitz J, Slyuzberg M, Ritsner M, Mark M, Popper M, Ginath Y. Changes in diagnosis in a 9-year national longitudinal sample. Comprehensive psychiatry. 1994;35(5):361-5.

7. Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Australian prescriber. 2015;38(5):152-5. Síntomas depresivos por el retiro de benzodiacepinas Foto: Anita